ClinicalTrials.gg
CompletedNCT07559708Updated Nov 3, 2026

A Study of the Sleepnet Elara APAP Device

An interventional study of Sleepnet Elara Treatment in Sleep Apnea - Obstructive, sponsored by Sleepnet Corporation. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Sleepnet Corporation · Not applicable, Interventional, and Treatment

How we know

Updated Nov 3, 2026Now CompletedNow Recruiting+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
89
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 755 studies in Sleep Apnea, Obstructive with a site in United States — 127 open to participants now, 162 under way, 9 of them phase 3. Sleep Apnea, Obstructive · United States.

Enrollment
186th of 596
89 · median 49
Started
2026
with 41 others
No phase
412 of 755
68 open now
Registered
732nd of 755
by date

Among the 755 studies in Sleep Apnea, Obstructive with a site in United States, this one is the 186th largest by enrollment of the 596 interventional ones that give a count, is one of 42 that started in 2026, is one of 412 with no phase, and was the 732nd registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

127 of the 755 studies in Sleep Apnea, Obstructive with a site in United States are open now. Recruiting first, the newest first:

122 more — sign in →

All 127 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 755 studies in Sleep Apnea, Obstructive with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to evaluate the effectiveness of the Elara APAP device.

Read the detailed description

A prospective open label study to assess the efficacy of the Elara APAP device when used in patients with obstructive sleep apnea. Subjects will sign Informed Consent and undergo screening/baseline and a 1 night in-lab PSG.

03

Conditions studied

  • Sleep Apnea - Obstructive

Keywords

  • OSA
  • Sleep Apnea
  • APAP
  • Polysomnography
  • Obstructive Sleep Apnea
  • Sleep Study
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Body weight ≥ 30kg
  2. Willing and able to consent, adhere to study requirements and receive mask treatment
  3. ≥ 18 years of age
  4. Diagnosed with OSA (Total AHI >15 events/hr) by a practicing physician within the last 6 months. A re-diagnosis may be necessary to establish current baseline AHI in case there has been significant weight change or other co-morbidities since the previous diagnosis (per PI discretion)
  5. Currently utilizing an APAP Device for ongoing treatment of OSA

Exclusion criteria

Exclusion Criteria:

  1. Body weight \< 30kg
  2. Female currently bearing a child or intending to become pregnant prior to the sleep study.
  3. Have implanted pacemaker, ICD or any other medical device that would interfere with the PSG results or safety of the subject undergoing the study
  4. Has pneumothorax, pneumomediastinum
  5. Has history of Cerebrospinal fluid leakage, craniocerebral trauma, intracranial trauma or pneumocephalus
  6. Ongoing shock from various causes untreated
  7. Current epistaxis
  8. Non-compliant with APAP usage (\< 4 hours per night on 70% of nights)
  9. Upper gastrointestinal bleeding that has not been effectively controlled
  10. Has obstructive vocal cord polyps
  11. Severe coronary heart disease with left heart failure
  12. Acute otitis media inflammation (must be resolved prior to sleep study)
  13. Excessive respiratory secretions and cough weakness
  14. Weak spontaneous breathing
  15. Tracheal intubation (nasal or oral) and tracheotomy
  16. Severe nasal congestion from various causes
  17. Lung bullae
  18. Central sleep apnea index >5 events/hr
  19. Have another significant sleep disorder(s) that in the opinion of the investigator would confound the results of the study (e.g. periodic leg movements >15/hr or insomnia that would interfere with completing the sleep study).
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
89 participants (actual)

Study arms

  • Experimental
    Treatment

    Sleepnet Elara Treatment

    Device: Sleepnet Elara Treatment

Interventions

  • DeviceSleepnet Elara Treatment

    Subject to have a 1 night in-lab PSG

06

What researchers measure

Primary outcomes

  1. AHI 4%

    The primary endpoint of this study is treatment night AHI 4%. A subject is considered a success if the Apnea Hypopnea Index calculated by using hypopneas that cause a 4% or greater drop in blood oxygen levels per hour of sleep (AHI4) measured during the 1-night treatment study (PSG) is less than 10 events/hour or less than 10% of the baseline AHI4 value determined at previous diagnosis, whichever is greater.

    Time frame: Day 1

07

Study locations

2 sites
  • University Sleep Disorders Center
    Auburn, Alabama 36832, United States
  • Clayton Sleep Institute
    St Louis, Missouri 63123, United States
08

References and documents

Individual participant data

Plan to share: No — Not required.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2026 to primary completion in Oct 2026, 5 months.

Of 118 industry-sponsored interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 21. This study's 5 months is below that.

Counting every sponsor, half of 629 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

Primary completion moved twice since we started tracking on Sep 25, 2026: Jun 2026 → Oct 2026, last on Nov 3, 2026.

Completion moved twice since we started tracking on Sep 25, 2026: Jun 2026 → Oct 2026, last on Nov 3, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2026
First posted
Apr 30, 2026
StartActual
Apr 21, 2026
Primary completionActual
Oct 20, 2026was Jun 2026
CompletionActual
Oct 20, 2026was Jun 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting→Completed
changed Oct 27, 2026 · changed Nov 3, 2026
Sites
1 site added. University Sleep Disorders Center is now Recruiting
Show site
  • Clayton Sleep Institute · St Louis, United States
Oct 27, 2026
Start date
Apr 27, 2026→Apr 21, 2026 (actual)
Oct 27, 2026
Primary completion
Jun 30, 2026→Oct 20, 2026 (actual)
moved 2 times, Oct 27, 2026 – Nov 3, 2026
Study completion
Jun 30, 2026→Oct 20, 2026 (actual)
moved 2 times, Oct 27, 2026 – Nov 3, 2026
Enrollment
55 (estimated)→89 (actual)
Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    Recruiting→Completed
    Primary completion Oct 30, 2026→Oct 20, 2026 (now actual)
    Study completion Oct 30, 2026→Oct 20, 2026 (now actual)
    Enrollment 55 (estimated)→89 (actual)
    + 2 other changes: contact details and site details
  2. Oct 27, 2026
    Not yet recruiting→Recruiting
    1 site added. University Sleep Disorders Center is now Recruiting
    Show site
    • Clayton Sleep Institute · St Louis, United States
    Start date Apr 27, 2026→Apr 21, 2026 (now actual)
    Primary completion Jun 30, 2026→Oct 30, 2026
    Study completion Jun 30, 2026→Oct 30, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07559708
Lead sponsor
Sleepnet Corporation
Responsible party
Sponsor
First posted
Apr 30, 2026
Start date
Apr 21, 2026
Primary completion
Oct 20, 2026
Completion
Oct 20, 2026
Last update
Nov 3, 2026

Study contacts

Anthony McLeod, MD
principal investigator · University Sleep Disorders Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion